Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib We here report the finding of a secondary FLT3 internal tandem duplication (FLT3-ITD) resistance mutation in a 70-year-old female patient with blast phase chronic myelomonocytic leukemia (CMML) and prior hematological response to sunitinib and sorafenib. At the time of presentation, the patient looked back on a 2-year history of leukocytosis. During this time, the disease fulfilled the 2008 WHO diagnostic criteria for CMML 1 on all occasions, with bone marrow aspirates revealing granulocytic hyperplasia, an increase of monocytic cells and bone marrow blast counts of 7, 7 and 15 per cent on three different occasions. Persistent monocytosis (between 15 and 36 G/L) was present in the peripheral blood. Marrow cytogenetics revealed a normal female karyotype. Marrow molecular genetic analysis showed a 84 base pair FLT3-ITD. Testing for Bcr-Abl was negative, and there were no NRAS or KRAS mutations. On admission, white blood cell (WBC) count was 132 G/L with 27% monocytes and 4% blasts. Platelet count was 105 G/L, hemoglobin 10 g/dl and lactate dehydrogenase was 1150 U/l (Figure 1a) . Treatment with hydroxyurea-controlled leukocytosis for a period of 16 months before a WBC count of 322 G/L with 74% peripheral blood blasts and 90% bone marrow blasts indicated transformation to blast phase. WBCs and absolute blast counts were increasing while the patient received cytarabine at a dose of 200 mg per day (Figure 1a ). Leukapheresis and doxorubicine decreased WBC counts to normal ranges with 37% blasts. After informed consent, compassionateuse treatment with sunitinib 37.5 mg OD was started, alternating with sorafenib 400 mg BID every 4 weeks because of thrombocytopenia (sunitinib) and deterioration of a pre-existing psoriasis (sorafenib). During a period of 9 months, WBC counts were between 2.1 and 14.8 G/L, platelets were between 44 and 140 G/L, and the patient was in good condition with normal activity. Clearance of leukemic blasts from peripheral blood was achieved during a period of 7 months, and bone marrow blasts decreased from 90 to 40%. Thus, the patient achieved hematological response and bone marrow response while receiving sunitinib alternating with sorafenib. Thereafter, WBC counts increased from 2.2 G/L with 1% blasts to 44 G/L with 60% blasts within 4 weeks. Bone marrow blasts increased from 40 to 90%. The patient died 1 year after the diagnosis of blast phase CMML had been made. Sequence analysis of the FLT3 kinase domain before treatment with sunitinib and sorafenib showed FLT3-ITD wild-type sequence, and at the time of progression revealed a novel, FLT3/A848P mutation ( Figure 1b ). To determine whether relapse and resistance were related to the mutation, we cloned FLT3-ITD/A848P and examined drug response in Ba/F3 cells ( Figure 1c ). FLT3-ITD/A848P shifted response to sorafenib 100-fold in comparison with unmutated FLT3-ITD, and 10-fold for sunitinib, strongly supporting the biological significance of FLT3-ITD as a drug target in this case.
FLT3 kinase inhibitors display clinical activity in the treatment of AML. [2] [3] [4] [5] [6] Although responses were short-lived in many patients, 2,3 sustained responses were reported, including single cases of complete molecular remissions. 6 Moreover, a single case of a patient with PKC412-resistant AML and a FLT3-ITD/ N676K resistance mutation has been described, 7 supporting the significance of FLT3 as drug target in AML. Ongoing clinical trials evaluate the activity of FLT3 inhibitors added to standard chemotherapy in AML.
The FLT3-ITD/A848P mutation identified in our patient mediated strong sorafenib and sunitinib resistance in vitro, but did not affect response to PKC412 (Figure 1c) , an FLT3 inhibitor currently evaluated in clinical trials. Consequently, our patient at the time of relapse upon selection of the FLT3-ITD/A848P mutation might have been benefited from PKC412. The finding of a FLT3-ITD/N676K exchange in the first part of the FLT3 tyrosine kinase domain (TK1) in the PKC412-resistant patient by Heidel et al. 7 and the identification of FLT3-ITD/ A848P (TK2) in our patient resistant to sorafenib and sunitinib well accords to in vitro data suggesting that PKC412 might be more vulnerable to TK1 exchanges, whereas sorafenib might be more prone to mutations of TK2. 8, 9 Thus, sequential therapy with different FLT3 inhibitors might be an option, like it is common practice with Abl kinase inhibitors in the treatment of CML.
Recently, Lee et al. 10 described an FLT3-ITD knockin mouse model resulting in myeloproliferative disease resembling CMML, and found 3.1% of 194 CMML cases to be positive for FLT3-ITD. These data point to a distinct subset of CMML characterized by activating FLT3 mutations, and these patients might benefit from FLT3 inhibitor therapy. Our patient already had developed AML before treatment with sorafenib and sunitinib was instituted. Still, it is tempting to speculate that CMML patients positive for FLT3-ITD might benefit from therapeutic FLT3 inhibition early in the course of disease before transformation to AML occurs.
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The authors declare no conflict of interest. Clonal chromosomal abnormalities in Philadelphia-negative cells (CCA/Ph-) have been identified in 3-15% of chronic myeloid leukemia (CML) patients with a partial or complete cytogenetic response (CCyR) to imatinib.
1 Trisomy 8 and deletions of chromosome 7 (either monosomy 7 or del 7(q)) account for the majority of cases, although a range of other karyotypic changes were seen at lower frequency. A recent study reported CCA/PhÀ in patients on dasatinib, indicating that the phenomenon is not limited to imatinib therapy. In some patients, CCA/PhÀ is associated with a myelodysplastic syndrome, and progression to acute myeloid leukemia has been reported.
1,2 A single-center report suggested inferior survival in newly diagnosed patients who develop CCA/Ph-. 3 However, a larger study found that CCA/Ph-does not adversely affect the prognosis of patients with a major cytogenetic response to imatinib, indicating that this is a mostly benign condition. 4 The reported incidence of CCA/Ph-is based on metaphase karyotyping, which is limited by the small number of cells analyzed and by the fact that only cells are assayed that can be induced to divide within the culture period. We thus hypothesized that conventional karyotyoping may underestimate the incidence of CCA/Ph-and decided to screen CD34 þ /CD38 À cells from a cohort of CML patients with a CCyR to tyrosine kinase inhibitor (TKI) therapy for abnormalities of chromosomes 7 and 8. This primitive cell compartment is known to be enriched for hematopoietic progenitor and stem cells. 5 We find CCA/Ph-in CD34 þ /CD38 À cells from 4 of 19 patients, suggesting that CCA/Ph-is more common than previously appreciated.
Patients and methods

Patients
Samples were from consecutive CML patients on TKI therapy who were undergoing bone marrow aspirates at the Oregon Health & Science University as part of their clinical care. The only selection criterion was a normal karyotype on the previous biopsy. At the start of TKI therapy, one patient (number 14) was in the accelerated phase, whereas all others were in the chronic phase. All patients provided informed consent to an institutional review boardapproved protocol. Control samples (normal bone marrow mononuclear cells) were purchased from a commercial supplier.
Cell selection
Mononuclear cells were separated from bone marrow by density gradient centrifugation using Ficoll (Nycomed, Oslo, Norway) and depleted of lineage-positive cells using an antibody cocktail and magnetic beads (Stem Cell Technologies, Vancouver, British Columbia, Canada). CD34 þ /CD38 À (and in some experiments CD34 þ /CD38 þ ) cells were sorted on a BD FACSARIA after staining with fluorescein isothiocyanateconjugated anti-CD34 and phycoerythrin-conjugated anti-CD38 monoclonal antibodies (BD Biosciences, San José, CA, USA). Sorted cells were sedimented at 1000 g and resuspended in 1.2 ml 3:1 methanol: acetic acid. Cells were then dropped onto glass slides and allowed to dry one drop at a time.
FISH
Interphase fluorescence in situ hybridization (I-FISH) for BCR-ABL was performed on 200 unselected bone marrow cells as part of routine diagnostics, using the Vysis ABL (9q34, red), ASS
